{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:18:16Z","timestamp":1789042696945,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This systematic review and network meta-analysis(NMA) was designed to compare the long-term outcomes of pembrolizumab monotherapy and pembrolizumab plus chemotherapy as first-line therapy for metastatic non-small-cell lung cancer(NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Four databases(Medline, Embase, Web of Science and CENTRAL were searched published from establishment of database to August 17, 2023, for articles studying pembrolizumab monotherapy or pembrolizumab plus chemotherapy for non-small cell lung cancer (NSCLC). Network meta-analyses of progression-free survival(PFS), overall survival(OS), objective response rate(ORR), treatment-related adverse events(trAEs) and immune-related adverse events(irAEs) were performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of five studies were considered for NMA. This NMA includes a cohort of 2878 patients diagnosed with advanced NSCLC. Among them, 791 patients received pembrolizumab monotherapy, 1337 patients received chemotherapy, and 748 patients received pembrolizumab plus chemotherapy. The IPDformKM software was utilized to reconstruct Kaplan-Meier curves for OS and PFS, offering a lucid and intuitive depiction of oncological outcomes. For patients who have high levels of programmed death-ligand 1(PD-L1) expression (\u226550%), pembrolizumab plus chemotherapy was more effective than using pembrolizumab alone as first-line therapy in terms of PFS (median survival time: 10.41 months versus 7.41 months, HR: 0.81, 95%CI 0.67 to 0.97, P=0.02) and ORR (RR:1.74, 95% CI: 1.25-2.43). Nevertheless, there was no statistically significant difference observed between the two groups in terms of OS (median survival time: 22.54 months versus 22.62 months, HR: 0.89, 95%CI 0.73 to 1.08, P=0.24). Furthermore, pembrolizumab plus chemotherapy provided a more advantageous long-term survival advantage in terms of OS (median survival time: 20.88 months versus 13.60 months, HR: 0.77, 95%CI: 0.62 to 0.95, P=0.015) compared to pembrolizumab monotherapy in patients with low PD-L1 expression levels (1% to 49%). With regards to safety, there was no statistically significant disparity between the two groups in relation to any irAEs (RD=0.02, 95% CI: -0.12 to 0.16) or Grade\u2265 3 irAEs (RD=0.01, 95% CI: -0.10 to 0.12). Nevertheless, pembrolizumab plus chemotherapy exhibited a greater likelihood of encountering any trAEs (RD=0.23, 95% CI: 0.17 to 0.30) and Grade\u2265 3 trAEs (RD=0.28, 95% CI: 0.21 to 0.35) in comparison to pembrolizumab monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present network meta-analysis reported comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer. Pembrolizumab plus chemotherapy led to improved PFS and ORR in patients with advanced NSCLC who had a PD-L1 expression level of 50% or above. However, there was no noticeable benefit in terms of OS when pembrolizumab was paired with chemotherapy compared to utilizing pembrolizumab alone. In addition, pembrolizumab plus chemotherapy offered a greater long-term survival benefit in terms of OS when compared to utilizing pembrolizumab alone in patients with PD-L1 expression levels ranging from 1% to 49%. Furthermore, the increased effectiveness of pembrolizumab plus chemotherapy was accompanied by an increase in adverse side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024501740.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1375136","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:33:25Z","timestamp":1720672405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Shibo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoshan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: Cancer J Clin"},{"key":"B2","volume-title":"Small Cell Lung Cancer","author":"Basumallik","year":"2023"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3583","article-title":"In vitro synergistic antitumor efficacy of sequentially combined chemotherapy\/icotinib in non\u2212small cell lung cancer cell lines","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2020.02.010","article-title":"Advances in the treatment of non-small cell lung cancer: Immunotherapy","volume":"41","author":"Patel","year":"2020","journal-title":"Clinics Chest Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: Basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2116273","article-title":"Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives","volume":"22","author":"Cella","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol: Off J Eur Soc Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1522300","article-title":"Pembrolizumab for the first-line treatment of non-small cell lung cancer","volume":"18","author":"Ninomiya","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ (Clinical Res ed)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cllc.2019.05.009","article-title":"First-line pembrolizumab versus pembrolizumab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: A systematic review and network meta-analysis","volume":"20","author":"Kim","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40425-019-0600-6","article-title":"First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy","volume":"7","author":"Zhou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"103660","DOI":"10.1016\/j.critrevonc.2022.103660","article-title":"Pembrolizumab alone or with chemotherapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"173","author":"Udayakumar","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol: Off Publ Int Assoc Study Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncology: Off J Am Soc Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123364","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ctrv.2017.10.002","article-title":"PD-1 blockade in advanced NSCLC: A focus on pembrolizumab","volume":"62","author":"Peters","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"Oncologist"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1746112","DOI":"10.1080\/2162402X.2020.1746112","article-title":"Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","article-title":"Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance","volume":"39","author":"Zitvogel","year":"2013","journal-title":"Immunity"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: A systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J Thorac oncology: Off Publ Int Assoc Study Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2642-4","article-title":"Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients","volume":"144","author":"Rojk\u00f3","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11373","DOI":"10.1038\/s41598-017-11949-9","article-title":"Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients","volume":"7","author":"Fujimoto","year":"2017","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms20102578","article-title":"Remarkable alteration of PD-L1 expression after immune checkpoint therapy in patients with non-small-cell lung cancer: Two autopsy case reports","volume":"20","author":"Takahashi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1362","article-title":"Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study","volume":"10","author":"Saluja","year":"2019","journal-title":"Res Synthesis Methods"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1375136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:33:31Z","timestamp":1720672411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1375136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2024.1375136"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1375136","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,11]]},"article-number":"1375136"}}